Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. (2008)

Peer-Reviewed Study · Zoungrana A, Coulibaly B, Sié A, Walter-Sack I, Mockenhaupt FP, Kouyaté B, Schirmer RH, Klose C et al. · February 20, 2008

Zoungrana A et al., 2008-02-20: Burkina Faso open-label randomized phase II trial in 180 children: methylene blue plus amodiaquine gave the highest day-28 cure rate (95%) versus standard artesunate-amodiaquine (82%), while methylene blue plus artesunate was worse (62%).

By day 28, the respective figure was lowest for MB-AS (62%), intermediate for the standard treatment AS-AQ (82%; p = 0.015), and highest for MB-AQ (95%; p<0.001; p = 0.03).

e1630

Zoungrana A et al., 2008-02-20: Burkina Faso open-label randomized phase II trial in 180 children: methylene blue plus amodiaquine gave the highest day-28 cure rate (95%) versus standard artesunate-amodiaquine (82%), while methylene blue plus artesunate was worse (62%). C9 Burkina Faso (Nouna; PLoS One 3(2):e1630, 2008; NCT00354380). Study type: open-label randomized controlled phase II trial, N=180 children aged 6-10. Oral methylene blue combined with artesunate or amodiaquine; doses in the paper. Comparator: local standard of care artesunate-amodiaquine. Funder/conflicts: authors declared no competing interests. Bearing PARTLY: one methylene blue combination beat the standard and one was clearly worse – a genuinely mixed result. Also filed as MTL-004 (claims C1, C9). Study type: randomized trial.